Free shipping on orders from 160 €from 160 € 3-vial Retatrutide 30 mg pack at 150 € See the packs
ORDER

CagriSema: what the trials show and the current status of the authorization

CagriSema combines two Novo Nordisk molecules, cagrilintide and semaglutide. It achieved one of the highest weight losses measured in phase 3 trials, but did not match tirzepatide in a head-to-head comparison. Here are the results, trial by trial, and the status of the dossier as of November 2026.

The Cagrilintide GuideCagrilintide 5 mg – €69.90

What is CagriSema?

CagriSema is not a new molecule. It is a combination of two peptides in a single weekly injection: cagrilintide, an amylin analog, and semaglutide, the active ingredient in Ozempic and Wegovy. The two act on different receptors, and their effects on appetite are additive. Its name simply combines the beginnings of the two names.

CagriSema is not authorized in any country. MyPeptide does not sell CagriSema or semaglutide: only cagrilintide is offered, as a research reagent.

The results of the REDEFINE and REIMAGINE trials

Novo Nordisk conducted two large phase 3 programs: REDEFINE, focused on weight, and REIMAGINE, focused on type 2 diabetes. The figures below are weight loss unless otherwise stated.

TrialParticipantsDurationCagriSemaComparator
REDEFINE 13,417 overweight or obese adults, without diabetes68 weeks-20.4%-3.0% (placebo)
REDEFINE 21,206 adults with type 2 diabetes68 weeks-13.7%-3.4% (placebo)
REDEFINE 4809 overweight or obese adults84 weeks-20.2%-23.6% (tirzepatide)
REIMAGINE 22,713 adults with type 2 diabetes68 weeksHbA1c −1.91 pointsHbA1c −1.75 points (semaglutide alone)
Phase 2 (Frias et al., 2023)92 adults with type 2 diabetes32 weeks-15.6%−5.1% (semaglutide), −8.1% (cagrilintide)

In REDEFINE 1, 40.4% of participants who completed the treatment lost at least a quarter of their weight, for an average weight loss of 22.7% in this group. The 20.4% in the table refers to all participants, including those who discontinued treatment.

CagriSema or tirzepatide?

This was the most anticipated question, and the answer is not what Novo Nordisk hoped for. In the REDEFINE 4 trial, an open-label study conducted over 84 weeks against the maximum dose of tirzepatide (Mounjaro, Zepbound), CagriSema resulted in a weight loss of 20.2%, compared to 23.6% with tirzepatide. Among participants who completed the treatment, the figures were 23.0% and 25.5%, respectively. The primary endpoint, which aimed to demonstrate that CagriSema performed at least as well, was not met, according to Novo Nordisk's announcement of February 23, 2026.

In type 2 diabetes, the results are more favorable. In REIMAGINE 4, CagriSema performed at least as well as the maximum dose of tirzepatide on weight loss, but not on HbA1c. In REIMAGINE 5, with reduced doses on both sides, it resulted in a weight loss of 12.4%, compared to 9.1% with tirzepatide. These two results were only reported in Novo Nordisk's financial statements and have not yet been published in a scientific journal.

And what about semaglutide alone?

The addition of cagrilintide significantly improves the weight loss results of semaglutide. In REDEFINE 1, semaglutide alone resulted in a weight loss of 14.9%, compared to 20.4% for CagriSema. In REDEFINE 5, conducted in East Asia, the difference was 18.4% versus 11.9%. The benefit on HbA1c was smaller: -1.91 points versus -1.75 in REIMAGINE 2.

Tolerability

Digestive disorders are the most common side effects. In REDEFINE 1, they affected 79.6% of participants taking CagriSema, compared to 39.9% taking placebo, most often mild to moderate, and decreasing over time. Detailed figures, including those for cagrilintide alone, are available on the page side effects of cagrilintide.

What is the status of the authorization?

  • United States : application filed with the FDA on December 18, 2025, decision expected in the fourth quarter of 2026. On November 4, 2026, Novo Nordisk indicated it was preparing for a US launch in early 2027, subject to authorization.
  • Canada : application submitted to Health Canada in December 2025.
  • European Union : to our knowledge, no application to the European Medicines Agency has been publicly announced.

Novo Nordisk is continuing other trials, including REDEFINE 3 on cardiovascular events. A trial combining cagrilintide with a higher dose of semaglutide began in 2026, with results expected in 2028.

When will CagriSema arrive in France?

No date is known. To be sold in France, CagriSema must first be authorized at the European level, and then its price and reimbursement will be subject to a decision. Therefore, it currently has no public price in France, and products presented online as "CagriSema" are not authorized medicines.

Cagrilintide 5 mg – €69.90
One 5 mg lyophilized vial. Batch MP-777CG101 analyzed by Janoshik: purity 99.836%, 4.92 mg measured. Shipping from the European Union in 2 to 5 business days; delivery €10, free from €160.
Cagrilintide 5 mg – €69.90

Frequently asked questions

What is CagriSema?

The combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 analogue, in a weekly injection. It is developed by Novo Nordisk and is not yet approved in any country.

Is CagriSema more effective than Wegovy?

In REDEFINE 1, weight loss reached 20.4% with CagriSema versus 14.9% with semaglutide alone, the active substance in Wegovy, in 68 weeks.

CagriSema or Mounjaro: which one leads to the greatest weight loss?

In the REDEFINE 4 trial, tirzepatide (Mounjaro) performed better: 23.6% weight loss compared to 20.2% with CagriSema over 84 weeks. CagriSema did not demonstrate that it performed at least as well.

When will CagriSema be authorized?

In the United States, an FDA decision is expected in the fourth quarter of 2026. No European application has been announced to our knowledge, and no date is known for France.

What is the price of CagriSema?

It has no public price, since it is not authorized in any country.

Does MyPeptide sell CagriSema?

No. MyPeptide does not sell CagriSema or semaglutide. Only cagrilintide is offered, as a reagent intended exclusively for scientific laboratory research.

Sources: Garvey W.T. et al., N Engl J Med 2025 (REDEFINE 1); Davies M.J. et al., N Engl J Med 2025 (REDEFINE 2); Frias J.P. et al., Lancet 2023; Yamauchi T. et al., Lancet Diabetes Endocrinol 2026 (REDEFINE 5); Buse J.B. et al., 2026 (REIMAGINE 2); Novo Nordisk, announcements of 18/12/2025 and 23/02/2026, financial reports of 04/08/2026 and 04/11/2026. MyPeptide products are intended exclusively for scientific laboratory research.

FRENDEITESPTNLPLSV
Back to top